A randomized controlled trial to test the efficacy of trans-tympanic injections of a sodium thiosulfate gel to prevent cisplatin-induced ototoxicity in patients with head and neck cancer

Table 1 Baseline, treatment and intervention characteristics of the 13 trial participants

Age, years, mean SD	58 (8.0)
Sex, male, n %	10 (77)
Smoking, past or current, n %	7 (54)
Weight, kg, mean SD	78 (12)
Education, post-secondary, n %	6 (46)
Karnofsky, 100, n %	13 (100)
Comorbidity, ≥ 1, n %	3 (23)
HNC tumor site
Oral cavity, n %	4 (31)
Oropharynx, n %	6 (46)
Supraglottic, n %	1 (8)
Unknown, n %	2 (16)
Tumor stage
III, n %	3 (23)
IVA, n %	7 (54)
IVB, n %	3 (23)
Total Cisplatin dose received at the time of final audiologic evaluation, mg, mean SD	322 (145)
Radiation dose received by the cochlea on the treated side at the time of final audiologic evaluation, grays, mean SD	4.3 (4.5)
Radiation dose received by the cochlea on the control side at the time of final audiologic evaluation, grays, mean SD	7.0 (7.6)
Time between preparation of STS gel and trans-tympanic injection, minutes, mean SD	43.9 (27.5)
Time between trans-tympanic injection and Cisplatin treatment, hours, mean SD	20.6 (0.9)

ISSN: 1916-0216